Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › OLMA

Olema Pharmaceuticals

OLMA Lead: Phase 3 1 Biotech Distilled article ↓ 18 filings & releases ↓ Cash $48.6M (Jun 30, 2026) ↓ 1 verdict ↓ 1 timing quote ↓
Oncology Small Molecule

Market cap $641M 87.5M shares (10-Q, Aug 6, 2026) × $7.33 close Nov 6, 2026

Most recent annual filing: 2026-03-16

Catalyst timeline

11 trackedQuarter catalyst calendar →
  1. OP-3136 trial start4Q 2026OP-3136 trial start, 4Q 2026, routine
  2. Olema corporate updateNov 2026Olema corporate update, Nov 2026, routine
  3. Olema industry event readoutDec 8–11, 2026Olema industry event readout, Dec 8–11, 2026, notable
  4. Giredestrant PDUFA dateDec 18, 2026Giredestrant PDUFA date, Dec 18, 2026, major
  5. Palazestrant topline1Q 2027Palazestrant topline, 1Q 2027, thesis-defining
  6. Palazestrant NDA filing2027Palazestrant NDA filing, 2027, material
  7. Credit facility financingJan 31, 2027Credit facility financing, Jan 31, 2027, notable
  8. OP-3136 interim1H/mid-2027OP-3136 interim, 1H/mid-2027, notable
  9. Olema CEO leadership updateJun 8, 2027Olema CEO leadership update, Jun 8, 2027, routine
  10. Palazestrant + ribociclib topline2028Palazestrant + ribociclib topline, 2028, major
  11. Palazestrant FDA approval2028Palazestrant FDA approval, 2028, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Capital (as filed)

Cash
$48.6M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$412M Jun 30, 2026
Operating cash flow
−$45.9M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$461M cash, runway mid-2028 per the deep dive of Oct 27, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Olema Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-10-28 Watch Olema Pharmaceuticals (OLMA) - Scientific Deep Dive for Palazestrant, OP-3136 and Pipeline Products Palazestrant's investment case hinges on an ESR1 wild-type endpoint no oral degrader has ever won, supported only by a 21-patient subset at a dose the Phase 3 does not use, making the stock a watch until OPERA-01 data clarify the outcome.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (18)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 2, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)